Aduro Biotech to Host Research and Development Day in New York

BERKELEY, Calif., March 15, 2017 -- Aduro Biotech, Inc. (NASDAQ:ADRO) today announced that the Aduro management team will host a Research and Development Day in New York City, New York, on Monday, March 27, 2017, at 8:30 a.m. Eastern Time, to review its three distinct immunotherapy platform technologies and related clinical programs.  Leading immunotherapy expert Thomas Gajewski M.D., Ph.D., leader of the Immunology and Cancer program at the University of Chicago Comprehensive Cancer Center, Director of Melanoma Oncology, and a Professor in the Ben May Department for Cancer Research, will present on the STING (Stimulator of Interferon Genes) pathway as an important new therapeutic target and speak on its potential for groundbreaking innovation in immunotherapy. 

The following day, on Tuesday, March 28, Stephen T. Isaacs, chairman, president and chief executive officer of Aduro, and members of management, will ring the opening bell at the Nasdaq Stock Market. 

To access the live webcast and subsequent archived recording of the Research and Development Day and other Aduro presentations, please visit Aduro's website at www.aduro.com.

About Thomas Gajewski, M.D., Ph.D.
Dr. Gajewski is the leader of the Immunology and Cancer program at the University of Chicago Comprehensive Cancer Center, Director of Melanoma Oncology, and a Professor in the Ben May Department of Cancer Research. His research interests include the role of the STING pathway in immunity, the molecular and cellular regulation of T lymphocyte activation and differentiation, and the application of this information in immune-based cancer therapy. Dr. Gajewski has published more than 200 papers in peer-reviewed journals on basic aspects of T cell biology, anti-tumor immunity, and melanoma therapy. He was formerly President of the Society for Immunotherapy of Cancer, has served as an editor for Cancer Research and the Journal for Immunotherapy of Cancer and has received numerous awards and honors including the Burroughs Wellcome Fund Clinical Scientist Award for Translational Research and the American Cancer Society-Jules L. Plangere Jr. Family Foundation Professorship in Cancer Immunotherapy.

About Aduro
Aduro Biotech, Inc. is an immunotherapy company focused on the discovery, development and commercialization of therapies that transform the treatment of challenging diseases. Aduro's technology platforms, which are designed to harness the body's natural immune system, are being investigated in cancer indications and have the potential to expand into autoimmune and infectious diseases. Aduro's LADD technology platform is based on proprietary attenuated strains of Listeria that have been engineered to express tumor-associated antigens to induce specific and targeted immune responses. This platform is being developed as a treatment for multiple indications, including mesothelioma, ovarian, lung and prostate cancers. Additionally, a personalized form of LADD, or pLADD, is being developed utilizing tumor neoantigens that are specific to an individual patient’s tumor. Aduro's STING Pathway Activator platform is designed to activate the STING receptor in immune cells, resulting in a potent tumor-specific immune response. ADU-S100 is the first STING Pathway Activator compound to enter the clinic and is currently being evaluated in a Phase 1 study in patients with cutaneously accessible metastatic solid tumors or lymphomas. Aduro’s B-select monoclonal antibody platform includes a number of immune modulating assets in research and preclinical development. Aduro is collaborating with leading global pharmaceutical companies to expand its products and technology platforms. For more information, please visit www.aduro.com.

Cautionary Note on Forward-Looking Statements 

This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements regarding our intentions or current expectations concerning, among other things, our technology platforms, plans, and the potential for eventual regulatory approval of our product candidates. In some cases, you can identify these statements by forward-looking words such as “may,” “will,” “continue,” “anticipate,” “intend,” “could,” “project,” “seek,” “potential,” “expect” or the negative or plural of these words or similar expressions.  Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that could cause actual results and events to differ materially from those anticipated, including, but not limited to, our history of net operating losses and uncertainty regarding our ability to achieve profitability, our ability to develop and commercialize our product candidates, our ability to use and expand our technology platforms to build a pipeline of product candidates, our ability to obtain and maintain regulatory approval of our product candidates, our ability to operate in a competitive industry and compete successfully against competitors that have greater resources than we do, our reliance on third parties, and our ability to obtain and adequately protect intellectual property rights for our product candidates.  We discuss many of these risks in greater detail under the heading “Risk Factors” contained in our annual report on Form 10-K for the year ended December 31, 2016, which is on file with the Securities and Exchange Commission. Any forward-looking statements that we make in this press release speak only as of the date of this press release. We assume no obligation to update our forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release. 

Contact:			
Sylvia Wheeler		
SVP, Corporate Affairs	
510 809 9264			

Media Contact:
Susan Lehner
510 809 2137
[email protected]